Aim. To review several studies on botulinum toxin in the treatment of post-stroke patients.
Review. Ten studies (out of which 9 were randomised controlled trials) on botulinum toxin type A (BTX-A) treatment in post-stroke patients were analysed. Both homogeneity of the patient group in terms of the diagnosis and the patients' comparability in terms of their functional prognosis and other sources of bias were generally unsatisfactory. BTX-A treatment effectiveness could not be convincingly demonstrated as regards improvement of functional abilities. Larger-scale controlled studies are needed to assess BTX-A, and special attention should be paid to individual goal assessment, duration of functional benefits, co-treatment, side effects, and cost effectiveness.